Intravenous immunoglobulin improved clinical outcomes in patients with myasthenia gravis and worsening weakness

September 2007
ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p50
Academic Journal
The article discusses the effectiveness of intravenous immunoglobulin in improving the clinical outcomes in patients with myasthenia gravis and worsening weakness. It is stated that in patients with myasthenia gravis and worsening weakness, intravenous immunoglobulin (2 g/kg) was more effective than placebo for improving clinical outcomes on day 14, and the effect remained on day 28. Details of the therapeutic study and a table on the same are also provided.


Related Articles

  • Intravenous immunoglobulin improved clinical outcomes in patients with myasthenia gravis and worsening weakness: COMMENTARY. Nicolle, Michael W. // ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p50 

    The article offers the author's comments on intravenous immunoglobulin (IVIG) improved clinical outcomes in patients with myasthenia gravis (MG) and worsening weakness. It is stated that acute severe bulbar or respiratory weakness, a myasthenic crisis, can be life-threatening. It suggests that...

  • Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. Nemoto, Y.; Kuwabara, S.; Misawa, S.; Kawaguchi, N.; Hattori, T.; Takamori, M.; Vincent, A. // Journal of Neurology, Neurosurgery & Psychiatry;May2005, Vol. 76 Issue 5, p714 

    Objectives: To compare the clinical and electrophysiological features of myasthenia gravis (MG) patients with (seropositive) or without (seronegative) antibodies to acelylcholine receptor. To investigate whether antibodies to muscle specific kinase (MuSK) and ryanodine receptor (RyR) are...

  • Unsatisfactory outcomes in myasthenia gravis: influence by care providers. Dunand, Murielle; Botez, Stephan A.; Borruat, François-Xavier; Roux-Lombard, Pascale; Spertini, François; Kuntzer, Thierry // Journal of Neurology;Mar2010, Vol. 257 Issue 3, p338 

    Myasthenia gravis (MG) can be difficult to treat despite an available therapeutic armamentarium. Our aim was to analyze the factors leading to unsatisfactory outcome (UO). To this end we used the Myasthenia Gravis Foundation of America classification system. Forty one patients with autoimmune MG...

  • Myasthemia and me. Jones, LeAnna // RN;Jun76, Vol. 39 Issue 6, p50 

    Presents a case report on a patient with myasthenia gravis. Symptoms of myasthenia; Drug taken by patients with myasthenia; Adverse effects of the medicine.

  • Autonomic 'myasthenia': the case for an autoimmune pathogenesis. Drachman, Daniel B. // Journal of Clinical Investigation;3/15/2003, Vol. 111 Issue 6, p797 

    Presents the criteria for recognizing antibody-mediated autoimmune disease. Presence of autoantibodies in patients with the disease; Interaction of the antibody with the target antigen; Reduction of antibody levels.

  • Successful low-dose azathioprine for myasthenia gravis despite hepatopathy from primary sclerosing cholangitis: a case report. Finsterer, Josef; Höflich, Sonja // Journal of Medical Case Reports;2010, Vol. 4 Issue 1, p1 

    Introduction: Although myasthenia gravis is frequently associated with other disorders, it has not been reported together with primary sclerosing cholangitis, complicating the administration of liver-toxic immunosuppressive therapy. Case presentation: A 73-year-old Caucasian woman with a history...

  • Myasthenic Antibodies and Disease Phenotype. Rubin, Michael // Neurology Alert;Feb2013, Vol. 31 Issue 6, p43 

    The article discusses the author's views on a study regarding the clinical differences in patients with myasthenia gravis (MG) based on the type of existing antibody. The author explains that patients with MG demonstrate antibodies in the serum directed against acetylcholine receptor antibodies,...

  • Postoperative myasthenic crisis successfully treated with immunoadsorption therapy. Ishizeki, Junko; Nishikawa, Koichi; Kunimoto, Fumio; Goto, Fumio // Journal of Anesthesia;2005, Vol. 19 Issue 4, p320 

    Myasthenia gravis (MG) is an autoimmune disorder characterized by loss of acetylcholine receptors (AChR) due primarily to the production of anti-AChR autoantibodies. We report a case of MG associated with elevated anti-acetylcholine receptor antibody (anti-AChR Ab) and refractory crisis after...

  • Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. Dalakas, Marinos C. // JAMA: Journal of the American Medical Association;5/19/2004, Vol. 291 Issue 19, p2367 

    Context Intravenous immunoglobulin (IVIG) enhances immune homeostasis by modulating expression and function of Fc receptors, interfering with activation of complement and production of cytokines, providing anti-idiotypic antibodies, and affecting the activation and effector functions of T and B...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics